With two new appointments, SAGA Diagnostics strengthens its Board of Directors and Scientific Advisory Board

SAGA Diagnostics AB, a premier provider of cancer genomics testing and non-invasive molecular diagnostics for precision oncology, today announces the appointment of veteran life science executive Gregory Batcheller as a member of the Company’s board of directors, and also the appointment of the world-renowned cancer biochemist Anne-Lise Børresen-Dale to the Company’s scientific advisory board.

“SAGA Diagnostics is at the forefront of cancer liquid biopsy diagnostic technology and these two new appointments to our advisory team will be invaluable as we expand,” stated Lao Saal, M.D., Ph.D., Founder and CEO for SAGA Diagnostics. “We look forward to their insights and guidance as we launch our new best-in-class ultrasensitive services and products for cancer companion diagnostics and non-invasive patient monitoring.”

Mr. Gregory Batcheller, J.D., LL.M., is an accomplished executive and dealmaker, as former CEO of DuoCort and NeuroVive, Partner at P.U.L.S., and co-founder of Laccure. He took NeuroVive to the stock market, has been involved with over a dozen companies, and is currently involved with a number of ventures including Xintela AB and Monocl Software.

Dr. Anne-Lise Børresen-Dale, Ph.D., Professor Emerita, is one of the world’s most distinguished cancer scientists. She has been Professor of Molecular Tumor Biology at University of Oslo since 1992, former president of the European Association for Cancer Research, and headed the Department of Genetics at the Norwegian Radium Hospital. Dr. Børresen-Dale has authored over 500 publications and received numerous awards and distinctions for her research.

SAGA Diagnostics was founded in February 2016 and is in the process of expanding operations and raising additional capital. The Company focuses on the measurement and analysis of circulating tumor DNA (ctDNA), a new type of biomarker found in the blood and other bodily fluids (so-called “liquid biopsies”) that offers an unprecedented window to the cancer disease state. SAGA’s proprietary tests can help patients, oncologists, and drug developers to detect actionable mutations, stratify patient groups, and monitor treatment response.

“SAGA Diagnostics is an exciting company with the potential to greatly accelerate personalized oncology. I am very pleased to be joining in a phase of intense development and growth”, said Greg Batcheller, who has multiple board positions in private and public pharma companies.

“SAGA Diagnostics is a very timely formed company with high potential, focusing on genomics and markers in the circulation for both diagnosis, treatment selection, and follow-up in cancer patients. I am exited in being on their scientific advisory board”, said Anne-Lise Børresen-Dale, who is also an elected member of the Royal Norwegian Society of Science and Letters, the Norwegian Academy of Science and Letters, and the European Academy of Cancer Sciences.


Photographs and interviews available on request.


Contact: Lao Saal, CEO

Email: lao.saal@sagadiagnostics.com

Phone: +46 – (0)70 888 – 52 61


About SAGA Diagnostics AB

SAGA Diagnostics is a cancer genomics company offering tissue and blood-based molecular genetic tests and services for healthcare, biopharmaceutical companies, and academia. SAGA’s liquid biopsy-based analyses are part of the revolution in cancer companion diagnostics and monitoring. SAGA’s proprietary tests, which quantify circulating tumor DNA with industry-leading ultrasensitivity, can help patients, oncologists, and drug developers to detect actionable mutations, stratify patient groups, and monitor treatment response. For more information, please contact us. Follow us on Twitter @SAGAdiagnostics.